evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,783 questions · 10,022 findings · 882 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

UVA1 vs PUVA

Physician‐assessed changes in clinical signs · atopic eczema
1 finding from 1 review

UVA1 vs PUVA

Patient‐reported changes in symptoms ‐ not measured · atopic eczema

The review found no eligible studies for this question.

1 finding from 1 review

UVA1 vs PUVA

Investigator Global Assessment ‐ not measured · atopic eczema

The review found no eligible studies for this question.

1 finding from 1 review

UVA1 vs PUVA

Health‐related quality of life ‐ not measured · atopic eczema

The review found no eligible studies for this question.

1 finding from 1 review

NB‐UVB vs placebo

Patient‐reported changes in symptoms · atopic eczema

Summary of findings table ‐ NB‐UVB may leads to higher patient‐reported changes in symptoms compared with placebo (low certainty).

1 finding from 1 review

UVA1 vs PUVA

Withdrawals due to adverse events not measured · atopic eczema

The review found no eligible studies for this question.

1 finding from 1 review

NB‐UVB vs placebo

Investigator Global Assessment · atopic eczema

Summary of findings table ‐ NB‐UVB may leads to higher investigator Global Assessment (short‐term) compared with placebo (low certainty).

1 finding from 1 review

NB‐UVB vs placebo

Health‐related quality of life ‐ not measured · atopic eczema

The review found no eligible studies for this question.

1 finding from 1 review

NB‐UVB vs UVA1

Investigator Global Assessment ‐ not measured · atopic eczema

The review found no eligible studies for this question.

1 finding from 1 review

Aspirin vs vitamin K antagonist (VKA)

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs low molecular weight heparin

Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes major bleeding compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review